The negative results of the GATSBY trial delineated the limitations of T-DM1 in this indication, highlighting issues such as the high degree of tumor heterogeneity and the potential for dynamic changes in HER2 expression status following first-line therapy (39). Here, ERBB2 is linked to neoplasm.